Edgewise Therapeutics is advancing EDG-5506 through a Phase 2 study (FOX) aimed at assessing its safety and efficacy in children and adolescents with Duchenne muscular dystrophy (DMD) who have previously received gene therapy. The study's design includes a randomized, double-blind, placebo-controlled phase followed by an open-label extension, which may provide robust data on long-term safety and efficacy. Given the unmet medical need in DMD and the increasing focus on gene therapy, successful outcomes could position Edgewise favorably in a competitive landscape that includes established players in the DMD space. The market for DMD therapies is expanding, with a growing number of gene therapies and supportive treatments, indicating potential for significant commercial opportunity if EDG-5506 demonstrates positive results.